RecruitingNCT05350865

Thailand HDV Cohort

Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024


Sponsor

The HIV Netherlands Australia Thailand Research Collaboration

Enrollment

3,152 participants

Start Date

Jan 30, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Male or female, aged 18 years and older
  • Chronically-infected with HBV, as defined by:
  • Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result
  • Provide signed and dated informed consent form.

Exclusion Criteria1

  • Non chronic HBV

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

HIV-NAT, Thai Red Cross - AIDS Research Centre

Bangkok, Bangkok, Thailand

King memorial Chulalongkorn hospital

Bangkok, Bangkok, Thailand

Siriraj Hospital, Mahidol University

Bangkok, Bangkok, Thailand

Taksin Hospital

Bangkok, Bangkok, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05350865


Related Trials